UniProt P07948-1 · PDB · AlphaFold · Substrate: pEY · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 | 0.534 |
| 2 | Dasatinib | 99.6% | 0.4% | 87.97 | 0.699 |
| 3 | Tivozanib | 99.3% | 0.7% | 92.42 | 0.673 |
| 4 | Bosutinib | 98.9% | 1.1% | 87.22 | 0.555 |
| 5 | Repotrectinib | 98.7% | 1.3% | 84.21 | 0.608 |
| 6 | Vandetanib | 98.0% | 2.0% | 95.74 | 0.723 |
| 7 | Nintedanib | 97.9% | 2.1% | 90.23 | 0.608 |
| 8 | Erdafitinib | 97.8% | 2.2% | 95.71 | 0.737 |
| 9 | Ibrutinib | 95.7% | 4.3% | 94.74 | 0.723 |
| 10 | Ripretinib | 95.3% | 4.7% | 92.95 | 0.674 |
| 11 | Canertinib | 95.2% | 4.8% | 96.49 | 0.671 |
| 12 | Gilteritinib | 93.7% | 6.3% | 88.97 | 0.506 |
| 13 | Dacomitinib | 93.4% | 6.6% | 97.99 | 0.664 |
| 14 | Pacritinib | 92.4% | 7.6% | 88.64 | 0.452 |
| 15 | Alectinib | 92.4% | 7.6% | 95.49 | 0.651 |
| 16 | Sunitinib | 91.8% | 8.2% | 91.73 | 0.524 |
| 17 | Avapritinib | 91.4% | 8.6% | 97.73 | 0.644 |
| 18 | Crizotinib | 89.5% | 10.5% | 91.39 | 0.581 |
| 19 | Dabrafenib | 89.2% | 10.8% | 94.74 | 0.633 |
| 20 | Neratinib | 88.6% | 11.4% | 93.18 | 0.597 |
Paralog block
LYN, LYN_B
EMT expression
- Mesenchymal log2(TPM+1): 2.29
- Epithelial log2(TPM+1): 2.68
- Fold change: -0.39
- Status: No significant change
Selectivity landscape vs inhibition on LYN
Each point is one of the 92 approved drugs; color = inhibition % on LYN.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…